AbbVie has removed two early-stage antibody-drug conjugates in an update to its pipeline webpage, suggesting that the company is terminating the development of these candidates, Endpoints News reported Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,